Announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). The acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. BELLUS Health Inc shares T.BLU are trading up $9.58 at $19.29.
Stocks in play: BELLUS Health Inc
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
/Meta%20by%20creativeneko%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)